Barbara M. Grüner

This study identifies LOY as a driver of aggressive PDAC through epigenetic reprogramming, linking it to EMT and metastasis, and highlights its clinical relevance as a biomarker.

This study identifies artesunate as a drug that targets redox vulnerabilities in metastatic lung adenocarcinoma by exploiting glutathione-dependent mechanisms.

The paper introduces cellmig, a Bayesian tool for quantifying cell migration velocity with uncertainty, improving reproducibility and biological insight in high-throughput assays.

This study shows that loss of the Y chromosome in lung adenocarcinoma causes epigenetic and transcriptomic changes that increase lineage plasticity and poor clinical outcomes.

This paper compares the effects of USP7 inhibition and degradation in cancer cells, finding distinct phenotypic and proteomic responses.

BARMIX quantifies treatment resistance in gastrointestinal stromal tumor cell mixtures using barcoded experiments and probabilistic modeling, accurately reflecting clinical resistance patterns.

The paper establishes a database of lung cancer mouse models to improve data comparison and translational relevance by aligning mouse mutations with human lung cancer mutations.